Plasma HVA in psychiatric patients: longitudinal studies

Area of Science:

• Neuroscience
• Psychiatry
• Biochemistry

Background:

• Plasma homovanillic acid (pHVA) is a metabolite of dopamine, and its levels have been investigated as a potential biomarker for psychiatric disorders.
• Previous research suggested a correlation between elevated pHVA levels and psychotic symptoms, particularly in schizophrenia.

Purpose of the Study:

• To investigate the relationship between plasma homovanillic acid (pHVA) levels and clinical symptoms in schizophrenic patients undergoing antipsychotic treatment.
• To determine if pHVA levels correlate with symptom severity or changes in symptoms during treatment with trifluoperazine.

Main Methods:

• 40 inpatients (25 schizophrenic, 15 non-schizophrenic) underwent drug washout.
• Schizophrenic patients received 4 weeks of trifluoperazine treatment.
• Weekly behavioral assessments (Brief Psychiatric Rating Scale - BPRS) and plasma homovanillic acid (pHVA) measurements were collected.

Main Results:

• Baseline pHVA showed no correlation with age, sex, washout duration, diagnosis, or initial behavioral scores.
• In schizophrenic patients, pHVA levels did not significantly change during 4 weeks of trifluoperazine treatment.
• Clinical symptom improvement was not associated with changes in pHVA levels.
• No correlation was found between changes in Brief Psychiatric Rating Scale (BPRS) factors and changes in pHVA.

Conclusions:

• The findings do not support a direct relationship between plasma homovanillic acid (pHVA) levels and the severity or treatment response of psychotic symptoms in schizophrenia.
• Results suggest that the previously reported association between pHVA and psychosis may require re-evaluation and careful interpretation.